Joseph H. Capper
Joseph H. Capper's purchase track record
Joseph H. Capper has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/14/2026 | TELA | $167K | pending | pending | — |
| 5/2/2025 | MDXG | $1.27M | +13.3% | +21.0% | +20.3% |
| 6/22/2023 | MDXG | $640K | +20.9% | +41.0% | +8.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ANIK Stock Moves Amid Broader Biotech Sector News. Recent news coverage focuses on clinical trial results from other biotech companies like Merck and Amgen, rather than specific new developments for Anika Therapeutics. One article examines whether ANIK is outperforming other medical stocks this year. The stock currently trades within its 52-week range, with analysts maintaining a target price of $21.00.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification. A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
STIM shifts focus from devices to psychedelic infrastructure. Neuronetics announced it is moving away from solely manufacturing its TMS device and is building a platform to support psychedelic therapies. The change aims to broaden the company's role in the emerging mental-health market. The stock is currently trading near its $1.19 support level and has an RSI of 25.4, indicating a low momentum environment.
Transaction History
| TELA | ▲ Buy | Open Market | 25,000 | $31K | 9/17/2026 | View on chart |
| TELA | ▲ Buy | Open Market | 50,000 | $58K | 9/16/2026 | View on chart |
| TELA | ▲ Buy | Open Market | 50,000 | $53K | 9/15/2026 | View on chart |
| TELA | ▲ Buy | Open Market | 25,000 | $26K | 9/14/2026 | View on chart |
| TELA | ▲ Buy | Grant | 6,227 | $5K | 7/15/2026 | View on chart |
| ANIK | ▲ Buy | Grant | 10,402 | $0 | 6/18/2026 | View on chart |
| TELA | ▲ Buy | Grant | 11,675 | $0 | 6/9/2026 | View on chart |
| TELA | ▲ Buy | Grant | 11,925 | $0 | 6/9/2026 | View on chart |
| MDXG | ▲ Buy | Grant | 371,094 | $0 | 3/4/2026 | View on chart |
| ANIK | ▲ Buy | Grant | 14,164 | $0 | 6/20/2025 | View on chart |
| MDXG | ▲ Buy | Open Market | 200,000 | $1.3M | 5/2/2025 | View on chart |
| MDXG | ▲ Buy | Grant | 223,268 | $0 | 3/3/2025 | View on chart |
| ANIK | ▲ Buy | Grant | 5,771 | $0 | 7/9/2024 | View on chart |
| ANIK | ▲ Buy | Grant | 468 | $0 | 6/3/2024 | View on chart |
| MDXG | ▲ Buy | Open Market | 42,025 | $273K | 6/23/2023 | View on chart |
| MDXG | ▲ Buy | Open Market | 57,975 | $367K | 6/22/2023 | View on chart |
| STIM | ▲ Buy | Grant | 36,364 | — | 5/25/2023 | View on chart |
| STIM | ▲ Buy | Grant | 5,783 | $0 | 1/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Craig-Hallum initiates coverage on TELA Bio with $2 target
Craig-Hallum has started tracking TELA Bio, assigning a price target of $2. This new analyst note aligns with the current average analyst target of $2.08. The stock is currently trading above its 52-week low of $0.50, with recent technical indicators showing momentum near the upper end of its recent range.
Craig-Hallum initiates coverage on TELA Bio with $2 target. Craig-Hallum has started tracking TELA Bio, assigning a price target of $2. This new analyst note aligns with the current average analyst target of $2.08. The stock is currently trading above its 52-week low of $0.50, with recent technical indicators showing momentum near the upper end of its recent range.